ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $25.25 Consensus Price Target from Brokerages

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $25.25.

ACAD has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Raymond James reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. StockNews.com lowered shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Finally, Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $23.00 to $20.00 in a research report on Friday, January 3rd.

Insider Buying and Selling

In other news, COO Brendan Teehan sold 10,329 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $173,630.49. Following the transaction, the chief operating officer now owns 62,105 shares of the company’s stock, valued at $1,043,985.05. This trade represents a 14.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James Kihara sold 4,073 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $68,467.13. Following the transaction, the insider now owns 19,863 shares of the company’s stock, valued at approximately $333,897.03. This trade represents a 17.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,661 shares of company stock valued at $414,551 over the last 90 days. Company insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Park Place Capital Corp bought a new position in shares of ACADIA Pharmaceuticals in the third quarter worth about $25,000. Values First Advisors Inc. bought a new position in shares of ACADIA Pharmaceuticals during the third quarter worth $27,000. R Squared Ltd bought a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $47,000. Quest Partners LLC grew its holdings in ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,047 shares in the last quarter. Finally, Stonepine Capital Management LLC purchased a new stake in ACADIA Pharmaceuticals during the second quarter valued at $81,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ:ACAD opened at $18.66 on Monday. ACADIA Pharmaceuticals has a 1 year low of $14.15 and a 1 year high of $26.83. The stock’s 50-day moving average is $17.50 and its 200 day moving average is $16.64. The company has a market cap of $3.10 billion, a PE ratio of 23.92 and a beta of 0.37.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.14 by $0.06. The business had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The company’s revenue for the quarter was up 18.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.40) EPS. Analysts expect that ACADIA Pharmaceuticals will post 0.7 EPS for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.